Castle Biosciences Inc - Asset Resilience Ratio
Castle Biosciences Inc (CSTL) has an Asset Resilience Ratio of 36.13% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CSTL strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Castle Biosciences Inc's Asset Resilience Ratio has changed over time. See Castle Biosciences Inc net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Castle Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Castle Biosciences Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $197.92 Million | 36.13% |
| Total Liquid Assets | $197.92 Million | 36.13% |
Asset Resilience Insights
- Very High Liquidity: Castle Biosciences Inc maintains exceptional liquid asset reserves at 36.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Castle Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Castle Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Castle Biosciences Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Castle Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.59% | $182.78 Million | $578.56 Million | -1.05pp |
| 2024-12-31 | 32.64% | $173.42 Million | $531.24 Million | +0.82pp |
| 2023-12-31 | 31.82% | $144.26 Million | $453.34 Million | +1.49pp |
| 2022-12-31 | 30.33% | $135.68 Million | $447.33 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $462.57 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $22.40 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $9.82 Million | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more